UNLABELLED: BACKGROUND. A high throughput, high pressure liquid chromatographic (HPLC) method with triple quadrupole mass spectral detection (LC/MS/MS) was validated for the measurement of 5 endogenous androgens in human plasma and serum and applied to various in vivo and in vitro study samples to pursue a better understanding of the interrelationship of the androgen axis, intracrine metabolism, and castration-recurrent prostate cancer (CaP). METHODS: A Shimadzu HPLC system interfaced with a Sciex QTRAP 5500 mass spectrometer with electrospray ionization was used with in line column-switching. Samples were liquid/liquid extracted and chromatographed on a Luna C18(2) column at 60°C with a biphasic gradient using a 15-min run time. RESULTS: The method was validated for five androgens in human plasma and serum, and applied to four sets of samples. Plasma (n=188) and bone marrow aspirate (n=129) samples from patients with CaP, who received abiraterone acetate plus prednisone for up to 945 days(135 weeks), had undetectable androgens after 8 weeks of treatment. Plasma dehydroepiandrosterone(DHEA) concentrations were higher in African Americans than Caucasian Americans with newly diagnosed CaP. Analysis of prostate tumor tissue homogenates demonstrated reproducible testosterone (T) and dihydrotestosterone (DHT) concentrations with a minimal sample size of 1.0–2.0 mg of tissue. Finally, cell pellet and media samples from the LNCaP C4-2 cell line showed conversion of T to DHT. CONCLUSION: The proposed LC/MS/MS method was validated for quantitation of five endogenous androgens in human plasma and serum, and effectively profiles androgens in clinical specimens and cell culture samples.
UNLABELLED: BACKGROUND. A high throughput, high pressure liquid chromatographic (HPLC) method with triple quadrupole mass spectral detection (LC/MS/MS) was validated for the measurement of 5 endogenous androgens in human plasma and serum and applied to various in vivo and in vitro study samples to pursue a better understanding of the interrelationship of the androgen axis, intracrine metabolism, and castration-recurrent prostate cancer (CaP). METHODS: A Shimadzu HPLC system interfaced with a Sciex QTRAP 5500 mass spectrometer with electrospray ionization was used with in line column-switching. Samples were liquid/liquid extracted and chromatographed on a Luna C18(2) column at 60°C with a biphasic gradient using a 15-min run time. RESULTS: The method was validated for five androgens in human plasma and serum, and applied to four sets of samples. Plasma (n=188) and bone marrow aspirate (n=129) samples from patients with CaP, who received abiraterone acetate plus prednisone for up to 945 days(135 weeks), had undetectable androgens after 8 weeks of treatment. Plasma dehydroepiandrosterone(DHEA) concentrations were higher in African Americans than Caucasian Americans with newly diagnosed CaP. Analysis of prostate tumor tissue homogenates demonstrated reproducible testosterone (T) and dihydrotestosterone (DHT) concentrations with a minimal sample size of 1.0–2.0 mg of tissue. Finally, cell pellet and media samples from the LNCaP C4-2 cell line showed conversion of T to DHT. CONCLUSION: The proposed LC/MS/MS method was validated for quantitation of five endogenous androgens in human plasma and serum, and effectively profiles androgens in clinical specimens and cell culture samples.
Authors: Christina Wang; Don H Catlin; Laurence M Demers; Borislav Starcevic; Ronald S Swerdloff Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531
Authors: James L Mohler; Kris E Gaston; Dominic T Moore; Michael J Schell; Brian L Cohen; Catharina Weaver; Peter Petrusz Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: John J Stocking; Michael V Fiandalo; Elena A Pop; John H Wilton; Gissou Azabdaftari; James L Mohler Journal: J Natl Compr Canc Netw Date: 2016-09 Impact factor: 11.908
Authors: Won Kim; Li Zhang; John H Wilton; Gerald Fetterly; James L Mohler; Vivian Weinberg; Allison Morse; Russell Z Szmulewitz; Terence W Friedlander; Lawrence Fong; Amy M Lin; Andrea L Harzstark; Arturo Molina; Eric J Small; Charles J Ryan Journal: Clin Cancer Res Date: 2014-10-21 Impact factor: 12.531
Authors: Diya B Joseph; Gervaise H Henry; Alicia Malewska; Jeffrey C Reese; Ryan J Mauck; Jeffrey C Gahan; Ryan C Hutchinson; James L Mohler; Claus G Roehrborn; Douglas W Strand Journal: J Pathol Date: 2022-02-03 Impact factor: 7.996
Authors: Renjie Jin; Connor Forbes; Nicole L Miller; Douglas Strand; Thomas Case; Justin M Cates; Hye-Young H Kim; Phillip Wages; Ned A Porter; Krystin M Mantione; Sarah Burke; James L Mohler; Robert J Matusik Journal: Prostate Date: 2022-07-12 Impact factor: 4.012
Authors: David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Robert J Matusik; Ren J Jin; Simon W Hayward Journal: Prostate Date: 2016-05-16 Impact factor: 4.104
Authors: David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Alex Jang; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Jay H Fowke; Robert J Matusik; Ren J Jin; Simon W Hayward Journal: Prostate Date: 2015-12-28 Impact factor: 4.104
Authors: Michael V Fiandalo; John H Wilton; Krystin M Mantione; Carol Wrzosek; Kristopher M Attwood; Yue Wu; James L Mohler Journal: Prostate Date: 2017-12-01 Impact factor: 4.104
Authors: Ioana Lancrajan; Regine Schneider-Stock; Elisabeth Naschberger; Vera S Schellerer; Michael Stürzl; Ralf Enz Journal: J Cell Mol Med Date: 2015-03-30 Impact factor: 5.310
Authors: Michael V Fiandalo; John J Stocking; Elena A Pop; John H Wilton; Krystin M Mantione; Yun Li; Kristopher M Attwood; Gissou Azabdaftari; Yue Wu; David S Watt; Elizabeth M Wilson; James L Mohler Journal: Oncotarget Date: 2018-01-10